Mihai Gheorghiade


Affiliation: Northwestern University
Country: USA


  1. Gheorghiade M, Blair J, Filippatos G, Macarie C, Ruzyllo W, Korewicki J, et al. Hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure. J Am Coll Cardiol. 2008;51:2276-85 pubmed publisher
    ..In contrast to available inotropes, istaroxime increased SBP and decreased HR. (A Phase II Trial to Assess Hemodynamic Effects of Istaroxime in Pts With Worsening HF and Reduced LV Systolic Function [HORIZON-HF]; NCT00616161). ..
  2. Vaduganathan M, Gheorghiade M. Roadmap to inpatient heart failure management. J Cardiol. 2015;65:26-31 pubmed publisher
    ..Inpatient risk stratification should guide patient education, team structuring, disposition, and post-discharge monitoring. ..
  3. request reprint
    Gheorghiade M, Konstam M, Burnett J, Grinfeld L, Maggioni A, Swedberg K, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA. 2007;297:1332-43 pubmed
    ..clinicaltrials.gov Identifier: NCT00071331 ..
  4. request reprint
    Gheorghiade M, Greene S, Filippatos G, Erdmann E, Ferrari R, Levy P, et al. Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes. Eur J Heart Fail. 2012;14:1056-66 pubmed
    ..Given the lack of effect on dyspnoea and cardiac index and the hypotensive effect seen even with low doses, it is doubtful that further studies with intravenous cinaciguat would prove beneficial in this patient population. ..
  5. Gheorghiade M, Greene S, Ponikowski P, Maggioni A, Korewicki J, Macarie C, et al. Haemodynamic effects, safety, and pharmacokinetics of human stresscopin in heart failure with reduced ejection fraction. Eur J Heart Fail. 2013;15:679-89 pubmed publisher
    ..In HF patients with reduced LVEF and CI, ascending doses of JNJ-39588146 were associated with progressive increases in CI and reductions in SVR without significant effects on PCWP, HR, or SBP. NCT01120210. ..
  6. Wilcox J, Fonarow G, Ardehali H, Bonow R, Butler J, Sauer A, et al. "Targeting the Heart" in Heart Failure: Myocardial Recovery in Heart Failure With Reduced Ejection Fraction. JACC Heart Fail. 2015;3:661-9 pubmed publisher
    ..The identification of dysfunctional but viable myocardium and its diverse pathophysiological causes may provide opportunities to investigate existing and novel therapeutics aimed at enhancing myocardial recovery. ..
  7. request reprint
    Gheorghiade M, Teerlink J, Mebazaa A. Pharmacology of new agents for acute heart failure syndromes. Am J Cardiol. 2005;96:68G-73G pubmed
    ..Therefore, by using novel mechanisms of action, these agents may provide new opportunities for helping patients with AHFS. ..
  8. Gheorghiade M, Thyssen A, Zolynas R, Nadar V, Greenberg B, Mehra M, et al. Pharmacokinetics and pharmacodynamics of rivaroxaban and its effect on biomarkers of hypercoagulability in patients with chronic heart failure. J Heart Lung Transplant. 2011;30:218-26 pubmed publisher
    ..In vivo, hypercoagulability biomarkers appear to increase over time. Rivaroxaban reversed this trend for F1.2, and may reduce the rate of increase of DD and TAT in patients with stable, severe HF. ..
  9. Gheorghiade M, Vaduganathan M, Fonarow G, Bonow R. Rehospitalization for heart failure: problems and perspectives. J Am Coll Cardiol. 2013;61:391-403 pubmed publisher

More Information


  1. Greene S, Sabbah H, Butler J, Voors A, Albrecht Küpper B, Düngen H, et al. Partial adenosine A1 receptor agonism: a potential new therapeutic strategy for heart failure. Heart Fail Rev. 2016;21:95-102 pubmed publisher
  2. request reprint
    Gheorghiade M, Ambrosy A, Ferrandi M, Ferrari P. Combining SERCA2a activation and Na-K ATPase inhibition: a promising new approach to managing acute heart failure syndromes with low cardiac output. Discov Med. 2011;12:141-51 pubmed
  3. Mentz R, Greene S, Ambrosy A, Vaduganathan M, Subacius H, Swedberg K, et al. Clinical profile and prognostic value of anemia at the time of admission and discharge among patients hospitalized for heart failure with reduced ejection fraction: findings from the EVEREST trial. Circ Heart Fail. 2014;7:401-8 pubmed publisher
    ..URL: http://www.clinicaltrials.gov. Unique identifier: NCT00071331. ..
  4. Khan S, Campia U, Chioncel O, Zannad F, Rossignol P, Maggioni A, et al. Changes in serum potassium levels during hospitalization in patients with worsening heart failure and reduced ejection fraction (from the EVEREST trial). Am J Cardiol. 2015;115:790-6 pubmed publisher
    ..However, they are not associated with all-cause or CVM or HFH. Inhospital changes in potassium may limit the implementation of evidence-based therapies such as mineralocorticoid receptor antagonists. ..
  5. Gheorghiade M, Larson C, Shah S, Greene S, Cleland J, Colucci W, et al. Developing New Treatments for Heart Failure: Focus on the Heart. Circ Heart Fail. 2016;9: pubmed publisher
    ..The following discussion summarizes the key takeaway dialogue from this meeting. ..
  6. Senni M, Greene S, Butler J, Fonarow G, Gheorghiade M. Drug Development for Heart Failure With Preserved Ejection Fraction: What Pieces Are Missing From the Puzzle?. Can J Cardiol. 2017;33:768-776 pubmed publisher
    ..Recognizing that the study of HFpEF is inherently challenging and complex, addressing these specific areas and overcoming their respective hurdles might maximize the chances of discovering a beneficial therapy. ..